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EDITORIAL
2 2 JUL 1996
Should Family Doctors!
Refer Their Patients For
Mammography Screening?
In her research study published on page 315, Dr. Cindy Lam reports that a
pilot prosramme of mammography screening involving patients from a general
practice setting in Hong Kong showed that mammosraphy was both technically
feasible and acceptable to patients, although there was a low uptake by
women offered the chance of screening.
Feasible and acceptable it maybe, but is it advisable? Should we persuade
our patients to undergo mammography, despite their reluctance?
Family doctors wrestling with this dilemma are likely to receive very
conflicting advice. For example, in the B.M.J.1 a recent review of cancer
prevention in primary care concluded that primary care doctors have an
important role to play in encouraging women over the age of 50 to attend for
breast screening by mammography. This message was reinforced by an
advertisement in the Archives of Family Medicine which proclaimed October
1995 as National Breast Cancer Awareness Month in the U.S.A., and caught the
eye with the dramatic statement that "This year, over 46,000 women will die from
breast cancer If (your patient) doesn't make a mammogram
appointment, you can't help save her life."
At about the same time, however, the headlines of the leading story in the
British Sunday Times read2 "Pioneer resigns over 'useless' breast cancer tests",
and reported that one of the founders of the U.K.'s national breast screening
programme was calling for it to be scrapped on the grounds that
mammography was saving too few lives at too high a cost. His concerns were
echoed in a paper published in the Lancet3, which also argued that the benefits
achieved with screening mammography were marginal, and that the costs were
unsupportable by public funding.
Mammography has been hailed as an example of a successful mass
screening programme, and a variety of countries have set up national screening
programmes. Should Hong Kong follow suit?
A central problem seems to be that much of the writing about mammography
screening can only be described as wishful thinking and half-truths4, encouraged
by early trials promising a 30% reduction in mortality and completely ignoring
later and more sophisticated trials that have produced much less optimistic
results.
This wishful thinking has been reinforced by the tendency of researchers to
report the outcome of their trials in relative terms - the relative risk reduction in
breast cancer deaths - which is the percentage difference between breast
cancer deaths in the study and the control groups. A more practical measure is
the absolute risk reduction, which reports the number of women who would
have to undergo mammography for one death from breast cancer to be
prevented.
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Skrabanek5 has calculated the figures for the best
known screening trials. In the Health Insurance Plan of New
York6 trial, for example, a 35% relative risk reduction of dying
from breast cancer was obtained, which translates into
an absolute risk reduction in breast cancer deaths of 0.02%
and means that, if the trial results are correct, then 5061
women would have to be screened to prevent one breast
cancer death.
Paradoxically, trials of increasing sophistication have
demonstrated not greater benefits as might be expected,
but fewer. Thus the U.K. trial7 found a relative risk reduction
of 14%, which in statistical terms was not significant, but if
correct translates into an absolute risk reduction of 0.0006%
and means that 18,315 women would have to be
screened to prevent a death. The Malmo trial8 found a 5%
non-significant relative risk reduction, which if correct
means that 67,568 women have to be screened to
prevent a death.
With so many women needing to be screened, the costs
to the health care system are inevitably goins to be high.
Current estimates3 are that the mean annual cost per life
saved approaches $HK6,696,000.
What is often not taken into account by advocates of
screening are the emotional costs to the women involved.
False positive results, as demonstrated in Dr Lam's study,
are likely to be common, and lead to further investigation
and anxiety. 'A recent report from Sweden9 also
documents the substantial costs generated by the further
investigation of false positive mammograms. False negatives,
as a result of which women may be incorrectly reassured
that they do not have cancer, are also of concern, and it is
reported that some 10-15%10of early breast cancers are
missed by mammography.
Finally, even if an early breast cancer is identified, the
chance of the patient benefiting from the discovery is only
about 1 in 15. The problem is that the sophistication of
diagnosis of this particular cancer far exceeds the
sophistication of treatment11. Inevitably, this means that the
early detection of breast cancer in most women will make
no difference to the final outcome. They will, however,
know that they have cancer for much longer than they
would have done otherwise.
The potential for unsophisticated screening and
inadequate treatment of detected cancers is also a
problem, and even if the benefits of mammographic
screening were proved, care would need to be taken that
the diagnostic facilities provided a high level of technology
as well as skilled interpretation of films by experienced
radiologists. As well, those providing treatment would need
to be aware of the current data regarding trials of surgery,
chemotherapy and radiation therapy. Any small benefits of
screening could easily be wiped out by the risks of
inappropriate forms of intervention.
In Hong Kong, the situation is compounded by the fact
that breast cancer still seems to be less common than in
other places, despite the rising trend that has been
described12. However, given the relatively low prevalence
of this distressing disease, and the continuing debate in
countries that have already established expensive national
screening programmes, there would seem little justification
for a programme of mammographic screening in this
community at the present time, although mammography
will still be of use in patients with symptoms or signs of
breast disease. •
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